$72.82
10.07% yesterday
Nasdaq, Oct 02, 10:17 pm CET
ISIN
CH0334081137
Symbol
CRSP

CRISPR Therapeutics AG Target price 2025 - Analyst rating & recommendation

CRISPR Therapeutics AG Classifications & Recommendation:

Buy
61%
Hold
36%
Sell
3%

CRISPR Therapeutics AG Price Target

Target Price $80.58
Price $72.82
Potential
Number of Estimates 28
28 Analysts have issued a price target CRISPR Therapeutics AG 2026 . The average CRISPR Therapeutics AG target price is $80.58. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 36 analysts: 22 Analysts recommend CRISPR Therapeutics AG to buy, 13 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the CRISPR Therapeutics AG stock has an average upside potential 2026 of . Most analysts recommend the CRISPR Therapeutics AG stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 37.31 34.81
89.95% 6.71%
EBITDA Margin -1,198.90% -1,645.17%
2,095.58% 37.22%
Net Margin -981.64% -1,606.86%
2,272.21% 63.69%

29 Analysts have issued a sales forecast CRISPR Therapeutics AG 2025 . The average CRISPR Therapeutics AG sales estimate is

$34.8m
Unlock
. This is
8.53% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$135m 253.93%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $37.3m 89.95%
2025
$34.8m 6.71%
Unlock
2026
$156m 348.18%
Unlock
2027
$337m 115.85%
Unlock
2028
$864m 156.74%
Unlock
2029
$2.5b 190.47%
Unlock
2030
$5.9b 135.17%
Unlock
2031
$1.2b 79.92%
Unlock
2032
$1.6b 35.41%
Unlock

11 Analysts have issued an CRISPR Therapeutics AG EBITDA forecast 2025. The average CRISPR Therapeutics AG EBITDA estimate is

$-573m
Unlock
. This is
30.96% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-365m 16.47%
Unlock
, the lowest is
$-638m 45.91%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-447m 120.68%
2025
$-573m 28.01%
Unlock
2026
$-452m 21.10%
Unlock
2027
$-418m 7.40%
Unlock
2028
$-12.8m 96.94%
Unlock
2029
$258m 2,115.71%
Unlock
2030
$463m 79.24%
Unlock
2031
$914m 97.36%
Unlock
2032
$1.4b 48.37%
Unlock

EBITDA Margin

2024 -1,198.90% 2,095.58%
2025
-1,645.17% 37.22%
Unlock
2026
-289.62% 82.40%
Unlock
2027
-124.24% 57.10%
Unlock
2031
77.06% 882.91%
Unlock
2032
84.43% 9.56%
Unlock

32 CRISPR Therapeutics AG Analysts have issued a net profit forecast 2025. The average CRISPR Therapeutics AG net profit estimate is

$-559m
Unlock
. This is
19.55% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-386m 17.48%
Unlock
, the lowest is
$-635m 35.71%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-366m 138.43%
2025
$-559m 52.70%
Unlock
2026
$-388m 30.65%
Unlock
2027
$-316m 18.60%
Unlock
2028
$-146m 53.69%
Unlock
2029
$-13.9m 90.51%
Unlock
2030
$125m 997.55%
Unlock
2031
$286m 129.68%
Unlock
2032
$443m 54.69%
Unlock

Net Margin

2024 -981.64% 2,272.21%
2025
-1,606.86% 63.69%
Unlock
2026
-248.65% 84.53%
Unlock
2027
-93.77% 62.29%
Unlock
2028
-16.91% 81.97%
Unlock
2029
-0.55% 96.75%
Unlock
2030
2.11% 483.64%
Unlock
2031
24.13% 1,043.60%
Unlock
2032
27.56% 14.21%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -4.34 -6.33
123.71% 45.85%
P/E negative
EV/Sales 140.84

32 Analysts have issued a CRISPR Therapeutics AG forecast for earnings per share. The average CRISPR Therapeutics AG EPS is

$-6.33
Unlock
. This is
17.88% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-4.37 18.62%
Unlock
, the lowest is
$-7.18 33.71%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-4.34 123.71%
2025
$-6.33 45.85%
Unlock
2026
$-4.39 30.65%
Unlock
2027
$-3.57 18.68%
Unlock
2028
$-1.65 53.78%
Unlock
2029
$-0.16 90.30%
Unlock
2030
$1.41 981.25%
Unlock
2031
$3.24 129.79%
Unlock
2032
$5.01 54.63%
Unlock

P/E ratio

Current -13.56 10.30%
2025
-11.51 15.12%
Unlock
2026
-16.59 44.14%
Unlock
2027
-20.38 22.85%
Unlock
2028
-44.01 115.95%
Unlock
2029
-463.59 953.37%
Unlock
2030
51.66 111.14%
Unlock
2031
22.49 56.47%
Unlock
2032
14.54 35.35%
Unlock

Based on analysts' sales estimates for 2025, the CRISPR Therapeutics AG stock is valued at an EV/Sales of

140.84
Unlock
and an P/S ratio of
190.29
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 128.82 1,184.35%
2025
140.84 9.33%
Unlock
2026
31.42 77.69%
Unlock
2027
14.56 53.67%
Unlock
2028
5.67 61.05%
Unlock
2029
1.95 65.57%
Unlock
2030
0.83 57.48%
Unlock
2031
4.13 397.89%
Unlock
2032
3.05 26.15%
Unlock

P/S ratio

Current 174.06 773.42%
2025
190.29 9.32%
Unlock
2026
42.46 77.69%
Unlock
2027
19.67 53.67%
Unlock
2028
7.66 61.05%
Unlock
2029
2.64 65.57%
Unlock
2030
1.12 57.48%
Unlock
2031
5.58 397.89%
Unlock
2032
4.12 26.15%
Unlock

Current CRISPR Therapeutics AG Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Sep 23 2025
JP Morgan
Locked
Locked
Locked Sep 18 2025
HC Wainwright & Co.
Locked
Locked
Locked Aug 07 2025
Barclays
Locked
Locked
Locked Aug 06 2025
RBC Capital
Locked
Locked
Locked Aug 05 2025
Chardan Capital
Locked
Locked
Locked Aug 05 2025
B of A Securities
Locked
Locked
Locked Jul 22 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 23 2025
Locked
JP Morgan:
Locked
Locked
Sep 18 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 07 2025
Locked
Barclays:
Locked
Locked
Aug 06 2025
Locked
RBC Capital:
Locked
Locked
Aug 05 2025
Locked
Chardan Capital:
Locked
Locked
Aug 05 2025
Locked
B of A Securities:
Locked
Locked
Jul 22 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today